Global pharma major Lupin Limited (Lupin) announced that it has launched rivaroxaban tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the US FDA.
Rivaroxaban tablets USP, 2.5 mg, is bioequivalent to Xarelto tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated: to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD); to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.
Rivaroxaban tablets USP, 2.5 mg (RLD Xarelto) had estimated annual sales of USD 446 million in the US (IQVIA MAT January 2025).
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
